This article explains last week’s concrete developments affecting Humana (HUM): the insurer-led move to standardize pre-treatment reviews starting 2027 and industry forecasts of higher medical cost ratios for Q1. It assesses how these events may influence Humana’s operations, margins and near-term stock catalysts.

Humana’s stock remains under pressure after CMS’s muted Medicare Advantage rate proposal, a multi-billion-dollar Star Ratings headwind, and company moves to shrink unprofitable footprints and cut benefits. With no major new headlines this week, investors are focused on upcoming Q1 results and the final 2027 MA rate decision.

This week Humana (HUM) saw an analyst price-target cut, a $1B debt raise, reaffirmed 2026 guidance, network changes in Florida, and notable Medicare Advantage enrollment gains — all driving near-term stock volatility and strategic adjustments.

This week Humana (HUM) moved to bolster liquidity with a $1.0B junior subordinated notes offering while reporting a Q4 2025 loss and sharply lowered 2026 EPS guidance. Key drivers are Medicare Advantage Star Ratings, CMS rate actions, and elevated medical costs. Investors should watch upcoming CMS decisions, Star Ratings updates, and early 2026 operating metrics as potential catalysts for a recovery.

This article examines Humana’s recent $1 billion subordinated note offering and the OIG findings on unsupported Medicare Advantage diagnosis payments, explaining immediate financial and regulatory implications for HUM stock and what investors should monitor next.

Humana shares plunged after the company disclosed a $3.5B Medicare Advantage Star Ratings headwind, conservative 2026 guidance, an exit from unprofitable counties and a CMS proposal that implied nearly flat MA payment rates — all amplifying pressure on HUM stock.